A Case of Docetaxel Induced Myositis and Review of the Literature

Table 2

Documented case reports of taxane related myopathies.

Case	Demographics	Taxane other agents	Cancer type	Onset of muscle pathology	Treatment	Effect
Ardavanis et al. 2005 [2]	57, male	Docetaxel, gemcitabine	NSCLC	Day 7 after 4th cycle	Prednisone	Myositis of bilateral thighs
Hughes and Stuart-Harris, 2005 [3]	47, female	Docetaxel, epirubicin, and cyclophosphamide	Breast cancer, ER/PR+, HER2−	Day 11 after 2nd cycle	Prednisone	Myositis of bilateral thighs
Gidron et al., 2006 [4]	32, female	Paclitaxel, carboplatin	Hairy cell leukemia and thymoma	Day 7 after second cycle	IV corticosteroids, IVIG	Polymyositis and myocarditis (terminal)
Fardet et al., 2006 [5]	Unknown	Docetaxel or paclitaxel, agent unknown	Kaposi sarcoma	Unknown	Unknown	Unknown
Kalmadi et al., 2006 [6]	Unknown	Docetaxel and gemcitabine	NSCLC	Unknown	Unknown	Unknown
Sasaki et al., 2012 [7]	58, male	Paclitaxel, carboplatin	B cell thymoma	Day 18 after 2nd cycle	Not reported	Polymyositis, myocarditis (terminal)
Winkelmann et al., 2014 [8]	64, female	Paclitaxel, carboplatin	Ovarian adenocarcinoma	After second cycle	Methotrexate, prednisone	Polymyositis, scleroderma, Raynaud’s and GERD
Perel-Winkler and Derk, 2014 [9]	57, male	Paclitaxel and carboplatin	NSCLC	Months	Prednisone, plaquenil, methotrexate, and IVIG	Mucinous dermatomyositis
Current case: Perel-Winkler et al.	65, female	Docetaxel and cyclophosphamide	Breast cancer (ER/PR+, HER2−)	Day 8 after 3rd cycle	Prednisone	Bilateral proximal thigh myositis R > L